Goldman Sachs
SLDB icon

Goldman Sachs’s Solid Biosciences SLDB Stock Holding History

Goldman Sachs’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.74M Sell
935,535
-70,771
-7% -$455K ﹤0.01% 3416
2025
Q4 		$5.68M Buy
1,006,306
+329,679
+49% +$1.79M ﹤0.01% 3635
2025
Q3 		$4.17M Buy
676,627
+294,872
+77% +$1.72M ﹤0.01% 3812
2025
Q2 		$1.86M Buy
381,755
+201,618
+112% +$713K ﹤0.01% 4236
2025
Q1 		$667K Buy
180,137
+43,910
+32% +$188K ﹤0.01% 4998
2024
Q4 		$545K Buy
136,227
+26,629
+24% +$146K ﹤0.01% 5206
2024
Q3 		$764K Buy
109,598
+61,217
+127% +$496K ﹤0.01% 4819
2024
Q2 		$274K Sell
48,381
-155,367
-76% -$1.39M ﹤0.01% 5144
2024
Q1 		$2.71M Buy
+203,748
New +$1.91M ﹤0.01% 3628
2022
Q4 		– Sell
-9,337
Closed -$65K – 6240
2022
Q3 		$65K Sell
9,337
-16,198
-63% -$163K ﹤0.01% 5770
2022
Q2 		$236K Buy
25,535
+2,041
+9% +$21.2K ﹤0.01% 5567
2022
Q1 		$423K Sell
23,494
-8,817
-27% -$156K ﹤0.01% 5439
2021
Q4 		$848K Buy
32,311
+10,948
+51% +$335K ﹤0.01% 4993
2021
Q3 		$766K Buy
21,363
+17,670
+478% +$750K ﹤0.01% 4937
2021
Q2 		$203K Sell
3,693
-723
-16% -$47.8K ﹤0.01% 5735
2021
Q1 		$367K Buy
4,416
+963
+28% +$107K ﹤0.01% 5316
2020
Q4 		$392K Sell
3,453
-318
-8% -$20.1K ﹤0.01% 4752
2020
Q3 		$115K Buy
3,771
+183
+5% +$7.01K ﹤0.01% 5057
2020
Q2 		$158K Sell
3,588
-176
-5% -$7.31K ﹤0.01% 4877
2020
Q1 		$135K Sell
3,764
-1,746
-32% -$86.4K ﹤0.01% 4862
2019
Q4 		$368K Sell
5,510
-478
-8% -$52.8K ﹤0.01% 4661
2019
Q3 		$928K Buy
5,988
+3,429
+134% +$388K ﹤0.01% 4078
2019
Q2 		$221K Buy
2,559
+64
+3% +$6.98K ﹤0.01% 4744
2019
Q1 		$344K Buy
2,495
+1,003
+67% +$251K ﹤0.01% 4572
2018
Q4 		$600K Buy
1,492
+1,195
+402% +$562K ﹤0.01% 4252
2018
Q3 		$210K Sell
297
-78
-21% -$49K ﹤0.01% 4899
2018
Q2 		$201K Buy
+375
New +$115K ﹤0.01% 4989

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs's SLDB Position: Q1 2026 in Review

Goldman Sachs reduced its Solid Biosciences (SLDB) stake by 7% in Q1 2026, selling an estimated $455K and leaving 935,535 shares worth $6.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3416.

Goldman Sachs first reported a position in SLDB in Q2 2018 and has held it in 27 quarters since. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Goldman Sachs held 935,535 shares of Solid Biosciences worth $6.74M as of Q1 2026.
  • Goldman Sachs sold 70,771 Solid Biosciences shares in Q1 2026, an estimated $455K.
  • Solid Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3416 holding.
  • Goldman Sachs first reported a position in Solid Biosciences in Q2 2018 and has held it in 27 quarters since.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.